AI-powered MRI radiomics significantly improves prediction of treatment response in advanced liver cancer patients.
Key Details
- 1Multicenter study presented at ASCO 2025 focused on advanced hepatocellular carcinoma (HCC).
- 2AI-based radiomics model analyzed MRI data to predict response to atezolizumab and bevacizumab therapy.
- 3Study included 240 patients; training cohort of 161, validation cohort of 79.
- 4Radiomics model achieved AUC of 0.913 (training) and 0.825 (validation); combined with a key MRI feature, AUC increased to 0.951 and 0.835, respectively.
- 5Significant correlation found between radiomic and conventional MRI features for intrahepatic lesions.
Why It Matters
This work demonstrates the power of AI-driven radiomics to personalize cancer treatment planning, improve patient selection for liver cancer therapies, and highlights growing integration of advanced imaging analytics in clinical oncology workflows.
Source
AuntMinnie
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
AI Technique Unveils Previously Hidden MS Gray Matter Lesions on MRI
Researchers developed an AI-enhanced method to detect previously invisible gray matter lesions in multiple sclerosis using MRI.
•Radiology Business
Majority of Patients Want Disclosure When AI Used in Imaging
A new survey finds that nearly all patients want to be informed when AI is utilized in medical imaging interpretation.